Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Oncology and palliative care indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Biopsy, histology and molecular testing

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Purpose and principles

Select and sequence safe cancer tissue acquisition, preserve material for morphology and biomarkers, interpret an integrated pathology report, and manage inadequate or discordant results through multidisciplinary review.

Biopsy converts a clinical or radiological suspicion into a tissue diagnosis. The safest method balances diagnostic yield against bleeding, seeding, organ injury, anaesthetic burden and preservation of curative options. A superficially accessible metastasis may be preferable to a hazardous primary, while some lesions need excision intact or specialist biopsy-track planning. The responsible multidisciplinary team should determine the route when sarcoma, adrenal, testicular, ovarian, central nervous system or other pathway-sensitive tumours are possible.

Pathology proceeds from specimen identity and adequacy to morphology, immunophenotype and selected genomic or other biomarker testing. Grade, invasion, margins, lymphovascular spread and response to neoadjuvant therapy may be required depending on specimen. Molecular analysis has distinct diagnostic, predictive and inherited-risk roles. The report must state limitations, particularly after low cellularity, crush artefact, fixation delay or bone decalcification.

Discordance is a clinical finding. A benign or non-diagnostic sample does not safely overrule progressive imaging, and unexpected aggressive histology should prompt identity and radiology review. The next step may be deeper sections, additional staining, re-biopsy, a different lesion or definitive excision. Decisions belong in a multidisciplinary forum with radiology and pathology present.

Key points

  • Obtain tissue only when the result will change diagnosis or management and the route does not compromise later surgery, staging or safety.
  • The preferred biopsy is lesion- and pathway-specific: cytology, core biopsy, endoscopic sampling, marrow sampling or excision answer different questions.
  • Exclude procedure-specific hazards such as phaeochromocytoma, coagulopathy, vascular lesion and unsafe anatomical access before sampling.
  • Histological morphology and immunohistochemistry establish lineage; molecular tests refine classification, prognosis or treatment selection rather than replacing tissue context.
  • Plan fixation, transport and allocation before the procedure because decalcification, scant cells or exhausted blocks can prevent essential biomarkers.
  • A negative biopsy can mean no cancer, sampling error, necrosis or an unsuitable assay; radiology-pathology discordance requires review.
  • Do not request broad molecular panels without a defined decision, validated platform and plan for uncertain or possible germline findings.
  • Communicate the final integrated diagnosis, uncertainty, specimen adequacy and pending addenda to the treating multidisciplinary team.

Indications, selection and cautions

High-yield target

An accessible viable lesion with adequate solid tissue and low procedural risk is usually preferable to necrotic or technically hazardous disease.

Pathway-sensitive lesion

A suspected sarcoma, phaeochromocytoma or other tumour can be harmed by unplanned biopsy, requiring specialist discussion before needle placement.

Inadequate specimen

Scant tumour, crush, necrosis, poor fixation or decalcification may prevent diagnosis and biomarkers despite a technically completed procedure.

Discordant result

Benign histology that does not explain suspicious imaging, growth or examination should trigger combined pathology-radiology review.

Possible inherited finding

Tumour phenotype or molecular result may raise constitutional risk but requires consented germline confirmation before family action.

Method and interpretation

  1. 01
    Image-guided core biopsyFirst step
    Why
    Obtain architecture and material for immunohistochemistry and molecular testing.
    Interpretation and limitations
    Target viable enhancing tissue, plan a resectable track where relevant and balance core number against bleeding or organ risk.
  2. 02
    Fine-needle aspiration cytology
    Why
    Assess cells in selected thyroid, nodal or fluid lesions.
    Interpretation and limitations
    Cytology may be sufficient in defined pathways but often cannot show invasion or full architecture; a non-diagnostic aspirate needs planned escalation.
  3. 03
    Histology and immunohistochemistry
    Why
    Determine lineage, subtype, grade and relevant protein expression.
    Interpretation and limitations
    Interpret a panel rather than one stain, using internal controls and clinical-radiological context; poorly differentiated tumours may remain uncertain.
  4. 04
    Predictive molecular or protein biomarker
    Why
    Identify a validated treatment-selection marker.
    Interpretation and limitations
    Test the correct specimen at the correct disease stage and report assay, threshold framework and limitations; uncertain variants are not actionable.
  5. 05
    Germline confirmation

Clinical next steps

01PlanChoose the specimen and routeFirst stepImaging suggests malignancy and tissue confirmation will change care.+
  1. 1Review differential, staging imaging, accessible lesions, coagulation, medicines and tumour-specific hazards with the responsible team.
  2. 2DefinitiveSelect the least harmful route that provides enough tissue for morphology and mandatory biomarkers without compromising definitive surgery.
  3. 3Pre-alert pathology about suspected diagnosis, fresh-tissue or molecular requirements, infection risk and specimen transport.
02ReportBuild an integrated diagnosisThe laboratory receives a correctly identified sample.+
  1. 1Assess adequacy and morphology first, then use a focused immunohistochemical panel to establish or narrow lineage.

Risks, monitoring and follow-up

  • Observe the procedure-specific period for bleeding, pneumothorax, pain, infection, organ injury or sedation effects and give explicit return triggers.
  • Track the specimen from collection to accession and record whether fresh, fixed, cytogenetic or microbiology material was required.
  • Confirm final report and all molecular addenda reach the MDT; preliminary verbal impressions must not become the permanent diagnosis.
  • Audit tissue adequacy, repeat-biopsy rates, complications and biomarker failure by procedure and site.
  • Preserve remaining material and document exhaustion so future treatment teams know whether repeat tissue is needed.

Special situations

Biopsy is an intervention

Its route can seed a compartment, cause haemorrhage or remove tissue needed later, so planning matters as much as needle accuracy.

Architecture changes meaning

Cytology may identify malignant cells but cannot always demonstrate invasion, grade or spatial pattern needed for classification.

More testing uses tissue

Large panels can exhaust a small block and delay the few validated markers that determine current treatment.

Discordance needs a meeting

Pathology, radiology and clinical teams often resolve apparent contradiction by identifying sampling, labelling or disease-heterogeneity problems.

Tumour is not germline

A pathogenic variant in cancer tissue can be acquired; relatives need a confirmed constitutional result before predictive testing.

Common pitfalls

  1. 01

    Biopsying before checking tumour-specific hazards.

  2. 02

    Choosing a necrotic target because it is largest.

  3. 03

    Failing to plan a biopsy track for later excision.

  4. 04

    Exhausting scant tissue on low-value tests.

  5. 05

    Treating non-diagnostic tissue as benign.

  6. 06

    Acting on a molecular result without tumour context.

  7. 07

    Losing ownership of pending addenda.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Oncology and palliative careOriginal SBA

Discordant benign core

A growing radiologically suspicious mass has a core biopsy reported as benign fibrous tissue. What is the most appropriate interpretation and next step?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Oncology and palliative care topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Royal College of Pathologists cancer datasetsSpecimen handling, integrated diagnostic reporting and tumour-specific pathology data standards.
  • Genomics Education: constitutional versus somatic variantsInterpretation and confirmatory handling of a possible constitutional finding identified in tumour tissue.
  • NHS England cancer programmeMultidisciplinary diagnostic pathways and timely movement from tissue to treatment.
  • NICE shared decision making recommendationsConsent, uncertainty and discussion of procedural options and consequences.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Why
Establish whether a tumour clue represents inherited predisposition.
Interpretation and limitations
Use a non-tumour sample through genetics with consent; somatic findings alone cannot define relatives' risk.
2
Add validated molecular or predictive assays only where the result contributes to classification, prognosis, inherited risk or treatment selection.
  • 3Issue a structured report with specimen type, diagnosis, grade or stage elements, biomarker method, limitations and pending addenda.
    • 03ResolveManage an inadequate or discordant biopsyTissue is non-diagnostic or inconsistent with the clinical and radiological picture.+
    1. 1Confirm specimen identity and review slides with imaging to distinguish true benign tissue from sampling error or tumour heterogeneity.
    2. 2AlternativeDecide whether deeper sections, another assay, repeat core, alternative lesion or excision will answer the unresolved decision.
    3. 3DefinitiveContinue appropriate clinical surveillance or treatment of immediate complications while obtaining definitive evidence; do not let non-diagnostic mean discharged.